Neurogene Inc (NGNE)
40.33
+1.15
(+2.94%)
USD |
NASDAQ |
Sep 27, 16:00
40.32
-0.01
(-0.02%)
After-Hours: 20:00
Neurogene Cash from Operations (Quarterly): -15.89M for June 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -15.89M |
| March 31, 2024 | -21.65M |
| December 31, 2023 | -16.97M |
| Date | Value |
|---|---|
| September 30, 2023 | -11.57M |
| June 30, 2023 | -9.327M |
| March 31, 2023 | -13.56M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-21.65M
Minimum
Mar 2024
-9.327M
Maximum
Jun 2023
-14.83M
Average
-14.72M
Median
Cash from Operations (Quarterly) Benchmarks
| CEL-SCI Corp | -4.579M |
| AIM ImmunoTech Inc | -3.008M |
| IGC Pharma Inc | -1.752M |
| NovaBay Pharmaceuticals Inc | -0.578M |
| Protalix BioTherapeutics Inc | -3.61M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -23.61M |
| Cash from Financing (Quarterly) | 0.399M |
| Free Cash Flow | -66.82M |
| Free Cash Flow Per Share (Quarterly) | -0.9653 |
| Free Cash Flow Yield | -18.01% |